We previously reported that extending an overnight continuous posterior lumbar plexus nerve block to 4 days after hip arthroplasty provides clear benefits during the perineural infusion in the immediate postoperative period. However, it remains unknown whether the extended infusion improves subsequent health-related quality of life. METHODS: Patients undergoing hip arthroplasty received a posterior lumbar plexus perineural infusion of ropivacaine 0.2% from surgery until the following morning, at which time patients were randomized to continue either perineural ropivacaine (n ϭ 24) or normal saline (n ϭ 23) in a double-masked fashion. Patients were discharged with their catheter and a portable infusion pump, and catheters were removed on postoperative Day 4. Health-related quality of life was measured using the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index preoperatively and then at 7 days and 1, 2, 3, 6, and 12 mo after surgery. The WOMAC evaluates three dimensions of health-related quality of life, such as pain, stiffness, and physical functional disability (global score of 0 -96, lower scores indicate lower levels of symptoms or physical disability). For inclusion in the primary analysis, we required a minimum of three of the six timepoints, including Day 7 and at least two of Months 3, 6, and 12. RESULTS: The two treatment groups had similar global WOMAC scores for the mean area under the curve calculations (point estimate for the difference in mean area under the curve for the two groups [extended infusion group-overnight infusion group] ϭ 0.8, 95% confidence interval: Ϫ5.3 to ϩ 6.8 [Ϫ5.5% to ϩ 7.1%]; P ϭ 0.80) and at all individual timepoints (P Ͼ 0.05). CONCLUSIONS: This investigation found no evidence that extending an overnight continuous posterior lumbar plexus nerve block to 4 days improves (or worsens) subsequent health-related quality of life between 7 days and 12 mo after hip arthroplasty.
chronic pain, 3 and increasing joint motion may optimize subsequent functioning by decreasing the effects of immobilization on muscles and synovial joints. 4 Thus, there is indirect evidence that maximizing analgesia in the immediate postoperative period may reduce long-term pain, joint stiffness, and functional disability.
One intervention that has been shown to improve analgesia and decrease time to discharge readiness after hip arthroplasty is a continuous posterior lumbar plexus nerve block. 5, 6 Unlike traditional IV opioid administration or epidural infusion, a continuous posterior lumbar plexus nerve block may be continued after discharge using a portable infusion pump, providing extendedduration treatment without requiring prolonged hospitalization. 5, 7 Therefore, a continuous extended duration of posterior lumbar plexus nerve block after hip arthroplasty offers a theoretical possibility of "long-term benefits from a short-term intervention." 8 The most important outcomes for patients are measures of functional status and well-being. 9 These measures reflect the dimensions of health as they are conceptualized and valued by patients themselves. 10 Indeed, evaluating quality of life is explicitly recommended for chronic pain clinical trials in the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) consensus statement. 11 Although health-related quality of life is a subjective concept, various instruments are available to convert health status into quantifiable values. 11, 12 The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is an instrument specifically designed to evaluate clinically important patient-relevant changes in health-related quality of life after the treatment interventions in patients with osteoarthritis of the hip. 13, 14 The WOMAC evaluates three dimensions of health-related quality of life such as pain, stiffness, and physical functional disability. Whether the improved analgesia and accelerated time-todischarge readiness that result from a continuous posterior lumbar plexus nerve block translate into increased health-related quality of life remain unknown.
Therefore, we completed this prospective follow-up study of a previously reported, randomized, controlled, clinical trial. 5 We hypothesized that, as measured using the WOMAC instrument, the improvement in pain, stiffness, and functional ability would be greater not only at 1 wk but also at 1, 2, 3, 6, and 12 mo after hip arthroplasty in patients who received a 4-day continuous posterior lumbar plexus nerve block compared with those who received overnight continuous posterior lumbar plexus nerve block in the immediate postoperative period.
METHODS
The IRB (University of California San Diego, San Diego, California) approved all study procedures and all patients provided written, informed consent. Details of the study methods have been published previously. 5 In brief, patients who were offered enrollment included adults (18 -80 yr) with osteoarthritis scheduled for primary, unilateral hip arthroplasty via a 15-25-cm curvilinear lateral skin incision over the greater trochanter (either hip resurfacing or hip replacement via the posterior approach with a posterior capsulotomy) who desired a continuous posterior lumbar plexus nerve block for postoperative analgesia.
Study Intervention
Patients received a posterior lumbar plexus nerve block and perineural catheter (Contiplex, B. Braun Medical, Bethlehem, PA) followed by a perineural ropivacaine, 0.2%, infusion (8 mL/h basal; 4 mL patient-controlled bolus; 30-min lockout) from surgery until the following morning, at which time patients were randomized to either continue perineural ropivacaine (extended infusion, n ϭ 24) or switched to normal saline (overnight infusion, n ϭ 23). Randomization was performed in a triple-masked fashion (patients, investigators, statisticians) with stratification according to clinical site. Additional analgesics included 1 wk of oral acetaminophen (975 mg every 6 h) and either oral aspirin (650 mg daily, University of Florida) or celecoxib (200 mg every 12 h, University of California at San Diego). Patients were provided oral (oxycodone 5 mg tablets) and/or IV opioids (morphine sulfate 2-4 mg) for breakthrough pain.
At 18:00 on postoperative day (POD) 2 (36 h after randomization), a portable infusion pump (Pain Pump 2 Blockaid, Stryker Instruments, Kalamazoo, MI) containing 400 mL of the same study solution (basal 5 mL/h; bolus 4 mL; lockout 60 min) replaced the previous infusion pump. Patients were discharged with their pump and perineural catheter, in situ as early as 10:00 on POD 3. In the evening of POD 4, patients' caretakers removed the posterior lumbar plexus catheters, with physician instructions provided by telephone.
Outcome Measurements
This study was a preplanned secondary analysis of prospectively collected health-related quality-of-life data, as measured with the WOMAC questionnaire. This instrument evaluates three dimensions: pain, stiffness, and physical functional disability with 5, 2, and 17 questions, respectively. An ordinal Likert scale, from 0 to 4, is used for each question, with lower scores indicating lower levels of symptoms or physical disability. 13 Each subscale is summated to a maximum score of 20, 8, and 68, respectively. The individual dimensions are always analyzed separately, and investigators have often added a global score, which is calculated by summating the scores for the three subscales. 15, 16 As eloquently explained by Hajiro and Nishimura, 17 "Important concepts when evaluating measurements of health status are the clinically significant threshold or the minimal clinically significant difference. When health status is measured using a continuous scale, it needs to be known whether an observed difference indicates a clinically significant or trivial effect on the patients' health status or quality of life. A statistically significant difference in health status might be of little practical importance; it is more important to know the minimal clinically significant difference." Using the transition method, in an osteoarthritis rehabilitation intervention setting, effects larger than 12% of baseline score (6% of maximal score) can be attained and detected as the minimal clinically significant difference, by the WOMAC. 18 Since its inception 2 decades ago, the WOMAC has been translated into 60 languages and used in several hundred published clinical trials. 19 It has been rigorously examined, demonstrating excellent construct validity, responsiveness, and test-retest reliability in patients after hip arthroplasty 13,15,20 -23 and is, therefore, recommended in the Osteoarthritis International Research Society's guidelines for clinical trials. 19, [23] [24] [25] [26] The questionnaire may be selfadministered or administered via a telephone call and takes 5-10 min to complete. 20, 27, 28 Because it is a proprietary instrument, the questionnaire itself may not be published and is, therefore, not included in an appendix. Therefore, to investigate the relationship between the postoperative analgesic technique and the subsequent health-related quality of life, a baseline WOMAC was administered before surgery (POD 0) and again at 7 days and 1, 2, 3, 6, and 12 mo after the surgery. The baseline measurement was a self-administered written questionnaire, whereas subsequent measurements after hospital discharge were administered via telephone. Scores from self-administered and telephone-administered WOMAC instruments have a demonstrated error rate of only 0.9%-2.6%. 28 
Statistical Analysis
The study was powered for the two previously published primary end points: 1) time to attain three discharge criteria (adequate analgesia, independence from IV analgesics, and ambulation of at least 30 min) and 2) ambulatory distance in 6 min, the afternoon after surgery. 26 To analyze the WOMAC scores, the WOMAC responses were joined by straight lines among timepoints from POD 7 (t ϭ 0.25 mo) to t ϭ 12 mo. The personal progress estimated mean area under the curve was defined as the integral of this curve from 0.25 to 12, divided by 11.75 mo. The WOMAC hypotheses asked the question of whether overall personal means over a continuum for 12 mo of the WOMAC scores (mean area under the curve) differ between treatment groups.
The mean area under the curve measurements were compared by a two-sided t-test, with Satterthwaite correction for unequal variance as the primary question of the null hypothesis that the two groups have the same WOMAC profile over time. 29 To 27 Additional secondary analysis involved timepoint-by-timepoint comparisons for the raw values and for changes from baseline, also using the two-sided t-test with the Satterthwaite correction for unequal variance.
RESULTS
Details of the study results for the immediate postoperative period have been published previously. 5 For the mean area under the curve calculations, follow-up WOMAC data meeting our stringent inclusion criteria (a minimum of three of the six timepoints, including Day 7 and at least two of Months 3, 6, and 12) were available from 17 patients (71%) from the extended infusion and 17 (74%) patients from the overnight infusion groups. The two treatment groups had similar WOMAC scores for the mean area under the curve calculations (point estimate for the difference in mean area under the curve for the two groups [extended infusion groupovernight infusion group] ϭ 0.8, 95% confidence interval: Ϫ5.3 to ϩ 6.8 [Ϫ5.5% to ϩ 7.1%]; P ϭ 0.80). As expected from the statistical section, we obtained virtually the same P value (P ϭ 0.794) by a permutational t-test of the same question. For the remaining analyses, only three patients from the extended duration infusion group were completely lost to follow-up, resulting in available data for 44 patients (94%). However, the two treatment groups had similar WOMAC scores at all individual timepoints in terms of both raw scores and changes from baseline (P Ͼ 0.05; Figs. 1 and 2, and Tables 1 and 2) .
DISCUSSION
This prospective investigation found no evidence that extending an overnight continuous posterior lumbar plexus nerve block to 4 days improves subsequent health-related quality of life between 7 days and 12 mo after hip arthroplasty. Lack of treatment effects after perineural catheter removal contrasts with the benefits provided during the infusion, as demonstrated in two randomized, controlled trials. 5, 6 Benefits during the infusion included a decrease in postoperative pain, opioid requirements, opioid-related side-effects, and time to meet three critical discharge criteria. 5, 6 Absence of long-term benefit, from extended-duration posterior lumbar plexus perineural infusion, is disappointing as there are both theoretical reasons and clinical data suggesting that improving analgesia in the immediate postoperative period might decrease long-term pain, reduce joint stiffness, and improve functional status. [1] [2] [3] [4] However, extending the continuous posterior lumbar plexus nerve block to 4 days also resulted in no apparent outcome detriments, and, therefore, the previously reported continuous posterior lumbar plexus nerve block benefits in the immediate postoperative period are not negated by this WOMAC follow-up data. Of note, similar investigations involving the extension of femoral perineural infusion from 1 to 4 days after total knee arthroplasty found clear patient benefits during the infusion, 30 but no subsequent improvement in the health-related quality of life after catheter removal. 31 
Study Limitations
The WOMAC scores were secondary outcomes for the original study and, thus, do not have the statistical strength of primary outcomes. Although this study in and of itself has limited statistical power as similar studies that are completed by ourselves and others, it might be possible in the future to conduct a wellpowered meta-analysis of the randomized intervention with respect to mid-to long-term WOMAC scores. In addition, the individual means, variances, and covariances at and between the specific timepoints provided by this study may be used as planning parameters for future investigations. Future studies should consider the probable difficulties in contacting patients over the course of a full year. Of the 47 patients randomized in this study, only 34 (72%) provided a minimum of three of the six WOMACs, including Day 7 and at least two of Months 3, 6, and 12. Simple patient retention is far easier (in this study we had only three patients lost to follow-up) but collecting a nearly complete sample at all timepoints proved to be more challenging.
Furthermore, the intervention protocol used in this investigation reflected our clinical practice during the study period. However, few data are available to define the optimal posthip arthroplasty infusion protocol. Importantly, 43% of the ropivacaine group had their basal ropivacaine infusion halved the day after surgery because of quadriceps weakness versus 17% of the placebo group (Appendix). 5 It is possible that an alternative infusion protocol would result in different findings than those in this study. It is also noteworthy that, in this study, pain scores from 3 to 12 mo were exceedingly low for both treatment groups. Thus, it remains possible that in other patient populations with a higher risk of chronic posthip arthroplasty pain, an extended duration continuous lumbar plexus nerve block might yet provide a long-term benefit.
In summary, we previously reported that extending an overnight continuous posterior lumbar plexus nerve block to 4 days after hip arthroplasty provides clear benefits in the immediate postoperative period. However, the extended perineural infusion did not improve subsequent health-related quality of life between 7 days and 12 mo.
APPENDIX

Adverse Events
One patient from the Placebo group experienced a vasovagal episode on POD 3 at home, was readmitted and underwent a negative work-up for instigating conditions, and was discharged home the following day without negative sequelae. Patients from the ropivacaine group had their catheter inadvertently dislodged (evening POD 2), occlusive dressing inadvertently removed with subsequent purposeful catheter removal (morning POD 4), and catheter purposefully removed as requested by patient (morning of POD 3). One patient from the Placebo group had her infusion pump tubing disconnected from the catheter, and the catheter was subsequently purposefully removed out of concern for sterility (morning of POD 4). For purposes of analysis, each of these patients was retained in their respective treatment group per the intention-to-treat principle. One patient from the ropivacaine group requested study withdrawal, the afternoon of POD 1 in the belief that the perineural infusion was causing her nausea.
Three patients from the ropivacaine group experienced a fall during the infusion period. The first ambulated 13-18 min twice on POD 1 without apparent quadriceps weakness, self-administered local anesthetic boluses every 30 min after her afternoon therapy session, and then fell immediately upon attempting to stand without assistance that evening (she described her thigh as numb when she fell, which it had not been previously). The second patient ambulated over 30 min on five occasions over the course of 3 days without apparent quadriceps weakness, was discharged home on POD 3, lost her balance, then experienced what she described as a "slow, controlled fall" onto her buttocks, and was readmitted for 1 night. The third patient had experienced weak quadriceps on POD 1 and her basal infusion and bolus dose volumes were halved per study protocol, after which she ambulated over 30 min five times without difficulty. However, she experienced dizziness on POD 3 and fell that evening when attempting to walk without assistance; she had her catheter removed the following day and was discharged home without further incident. The patient attributed her fall to the dizziness (presumed etiology: anemia), which did not recur. None of these three falls resulted in physical injury.
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